A recently FDA-approved device has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent. When coupled with an innovative electrode placement planning system, the device facilitated the complete elimination of seizures in nearly half of the implanted patients enrolled in the decade-long clinical trials.